Commitment To Progress For Patients
- AbbVie’s oncology strategy is built on deep understanding of tumor biology and target identification — finding what’s overexpressed on cancer cells and building medicines around that science.
- ABBV-400, AbbVie’s next-generation antibody drug conjugate, has shown compelling activity across six tumor types: two forms of non-small cell lung cancer, colorectal, pancreatic, platinum-resistant ovarian, and head and neck cancers.
- AbbVie’s T-cell engager elranatamab is bringing immunotherapy to multiple myeloma — designed for efficacy, but also for patient convenience, allowing treatment closer to home with longer intervals between visits.
- The future of cancer care, as Abbvie sees it, is fully individualized — matching every patient to the therapy best suited to their tumor biology, with the goal of moving beyond remission toward cure.
The commitment, as Abidoye describes it, rests on two pillars: elevating the standard of care, and delivering therapies that genuinely improve patients’ lives. “It begins with the patient, it ends with the patient,” he says. “The patient is always at the center of what we do.”
Read MoreA Drug Built for Six Cancers
The most striking example of AbbVie’s approach on display at ASCO is ABBV-400, an investigational next-generation antibody drug conjugate targeting a protein known to be overexpressed across multiple tumor types. Rather than developing a drug for a single cancer and stopping there, AbbVie followed the biology — and found compelling activity across six separate disease indications: two types of non-small cell lung cancer, colorectal, pancreatic, ovarian, and head and neck cancers.Antibody drug conjugates, Abidoye explains, represent a fundamental shift in what cancer treatment can look like — delivering highly potent therapy with a much better safety profile, enabling patients to live longer and feel better on treatment. “Chemotherapy that previously had been the mainstay for treatment for a lot of patients,” he says, “could potentially become a thing of the past in some of these areas of high unmet need.”
Bringing Immunotherapy to Myeloma
In hematology, AbbVie is taking a proven playbook — it already has approved therapies in lymphoma and CLL — and pushing further. Its T-cell engager epcoritamab (Epkinly) has already brought new hope to patients with aggressive lymphoma. Now AbbVie is bringing similar technology to multiple myeloma with elranatamab, designed not just for efficacy, but for convenience — allowing patients to be treated closer to home, with longer intervals between visits and without hospitalization.
The Vision: A Therapy for Every Patient
Looking ahead, Abidoye’s excitement centers on something more fundamental than any single drug. He traces the arc of progress to put it in perspective: “We’ve come a long way from the point where patients had no treatment options available at all, to where patients had highly toxic therapies — some of which were worse than the actual disease — to now where we have multiple options that deliver highly efficacious therapies. But we’re not done.”
The destination, as he sees it, is full individualization — “a therapy that optimizes the patient and tumor characteristics to give the patient the best treatment, the longest longevity, and the best safety profile.” And beyond that, a word that was once unthinkable in oncology: cure. “That’s what motivates me, and I think that’s what motivates everybody at AbbVie.”
Learn more about SurvivorNet's rigorous medical review process.
